Article

Active Liposomal Targeting for Head and Neck Squamous Cell Carcinoma Treatment

2025-12-05

Abstract excerpt

Head and neck squamous cell carcinoma (HNSCC) is a major oncological challenge due to its high recurrence rates, biological heterogeneity, and poor long-term survival outcomes. Despite advances in surgery and radiotherapy, chemotherapeutic options are limited. Cisplatin (CDDP) remains the mainstay, while small molecule inhibitors, such as the selective PI3Kα inhibitor Alpelisib, are still under clinical evaluation...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4ab8d478-194f-592c-9593-f6fbe82e3c1a
DOI: 10.64898/2025.12.03.691158

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Active Liposomal Targeting for Head and Neck Squamous Cell Carcinoma TreatmentDOI 10.64898/2025.12.03.691158Read

Ligand conjugated lipid-based nanocarriers for cancer theranosticsSemantic proximity Read

The Role of Liposomal Drug Delivery in Modern Medicine and the Expanding Potential of NanocarriersSemantic proximity Read

Development and Optimization of Osimertinib-loaded Biodegradable Polymeric Nanoparticles Enhance In-vitro Cytotoxicity in Mutant EGFR NSCLC Cell Models and In-vivo Tumor Reduction in H1975 Xenograft Mice Models.Semantic proximity Read

Innovations and Mechanisms in Liposomal Drug Delivery: A Comprehensive IntroductionSemantic proximity Read

Liposomal Nanocarriers From Concept to Clinical ApplicationsSemantic proximity Read

Liposomal Formulations in Clinical Use Progress Challenges and Future DirectionsSemantic proximity Read

Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.Semantic proximity Read

Optimizing Niosome Formulations for Enhanced Cellular Applications: A Comparative Case Study with L-α-lecithin LiposomesSemantic proximity Read

Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.Semantic proximity Read

Nanoformulated cell-penetrating survivin mutant and its dual actions.Semantic proximity Read

Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.Semantic proximity Read

Efficacy of Nano-Formulated Nitazoxanide Compared to Bulk Powder Against Human Oral Squamous Cell Carcinoma Cell lineSemantic proximity Read